Comparison of conventional unstained lymph nodal harvesting vs methylene blue-stained lymph nodal harvesting in colorectal specimen in staging left-sided colorectal carcinoma: a randomized controlled trial

What Was Tested

The paper reports a study of Methylene blue (non-peptide stack partner), published as a randomized controlled trial.

The management and prognosis of colorectal carcinomas (CRCs) are related to the stage of the disease, which, in turn, relies on the lymph node harvest from the surgical specimen.

The guidelines recommend that at least 12 lymph nodes are required, which is not achieved in most resections.

Who Took Part

Patients who underwent elective surgery for left-sided CRCs with curative intent were randomized into 2 groups: stained and unstained.

In all patients, details of disease stage, history of neoadjuvant therapy, and number of isolated lymph nodes were recorded.

How the Study Was Run

In design terms this was a randomized and double-blind study.

Random assignment meant chance, not the researchers, decided who got Methylene blue (non-peptide stack partner) and who got the comparison, which limits bias.

As a double-blind Methylene blue (non-peptide stack partner) study, the assignments were hidden from both participants and investigators until the end.

The sample size was calculated as 66.

What Was Measured

Topics PubMed links to this paper include Methylene Blue, Lymph Nodes, Elective Surgical Procedures, Neoadjuvant Therapy, Transforming Growth Factor beta and Colorectal Neoplasms.

Author keywords: Colorectal carcinoma, Lymph node harvesting and Nodal staging.

What This Means in Plain Language

The paper is a randomized and double-blind study of Methylene blue (non-peptide stack partner).

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2024 (Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract), a journal based in Netherlands.

More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.